top of page

Certaines des recherches et publications mondialement connues

Ce sont toutes les données que nous avons pu trouver concernant le lien entre les histamines et le virus SARS-Cov-2 qui cause le Covid-19 ainsi que les possibles effets bénéfiques

des antihistaminiques dans le cadre d'un protocole de traitement précoce.

Abstract Lights
Azelastine - update 2021

01

CEBINA reports positive findings on the potency of azelastine, a widely used anti-histamine, as anti-COVID-19 approach.

​

CEBINA identifie un vaporisateur nasal antihistaminique courant comme potentielle approche anti-COVID-19.

02

COVID-19 Treatments: Study Shows Using Dual Antihistamines Such As Cetirizine And Famotidine Helps Pulmonary Symptoms In COVID-19 Patients.

Structure métallique
Abstract Lights

03

Famotidine, Histamine, Mast Cells and Mechanisms

04

Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.

Structure métallique
Abstract Lights

05

Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients.

06

Histamine release theory and roles of antihistamine in the treatment of cytokines storm of COVID-19 September-October 2020.

Structure métallique
Abstract Lights

07

Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome September 2020.

08

Existing antihistamine drugs show effectiveness against COVID-19 virus in cell testing December 2020.

Structure métallique
Abstract Lights

09

Some Novel Insights into Vitamin D with Interrelated Factors Determining the Outcome of Patient affected by COVID-19

Short running title: The Perfect Storm

Dr Annwyne Houldsworth

10

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases.

Structure métallique
Abstract Lights

11

Cardiovascular complications are rapidly emerging as a key threat in coronavirus disease 2019 (COVID-19) in addition to respiratory disease. The mechanisms underlying the disproportionate effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with cardiovascular comorbidities, however, remain incompletely understood.

12

Histamine and histamine intolerance.

Structure métallique
Abstract Lights

13

 A Pathogenic Pathway That May Link Interstitial Edema to Immunothrombosis.

14

The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets.

Structure métallique
Abstract Lights

15

Mast Cells in Alveolar Septa of COVID-19 Patients: A Pathogenic Pathway That May Link Interstitial Edema to Immunothrombosis.

16

Histamine intolerance results from a disequilibrium of accumulated histamine and the capacity for histamine degradation. Histamine is a biogenic amine that occurs to various degrees in many foods. In healthy persons, dietary histamine can be rapidly detoxified by amine oxidases, whereas persons with low amine oxidase activity are at risk of histamine toxicity...

Structure métallique
Abstract Lights

17

Reports that the over-the-counter histamine H2 receptor antagonist famotidine could help treat the novel coronavirus disease (COVID-19) appeared from April 2020. We, therefore, examined reports on interactions between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and histamine receptor antagonists...

18

Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?

Structure métallique
Abstract Lights

19

Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients.

20

Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis.

Structure métallique
Abstract Lights

21

A team of scientists from the United Kingdom has recently revealed the therapeutic benefits of histamine receptor antagonists in reducing long-term symptoms of coronavirus disease 2019 (COVID-19). 

22

Long-COVID following mild SARS CoV-2 infection: characteristic T cell alterations and response to antihistamines.

Structure métallique
Abstract Lights

23

Antihistamines and azithromycin as a treatment for COVID-19 on primary health care – A retrospective observational study in elderly patients.

24

A KZN doctor’s observations and treatment of COVID-19 may reveal a missing element.

Structure métallique
Abstract Lights

25

A potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19.

26

Histamine utilizes JAK–STAT pathway in regulating cytokine production.

Structure métallique
Abstract Lights

27

Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2.

28

Demystifying Excess Immune Response in COVID-19 to Reposition an Orphan Drug for Down-Regulation of NF-κB: A Systematic Review.

Structure métallique
Abstract Lights

29

Famotidine Against SARS-CoV2: A Hope or Hype?

30

COVID-19 and Multisystem Inflammatory Syndrome, or is it Mast Cell Activation Syndrome?

Structure métallique
Abstract Lights

31

COVID-19, microthromboses, inflammation, and platelet

activating factor.

32

Identification of SARS-CoV-2 entry inhibitors among already approved drugs.

Structure métallique
Abstract Lights

33

Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.

34

Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis.

Structure métallique
Abstract Lights

35

Potential association of mast cells with coronavirus disease 2019.

36

Repositioning of histamine H1 receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2.

Structure métallique
Abstract Lights

37

No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19.

38

Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2.

Structure métallique
Abstract Lights

39

Antihistamine and cationic amphiphilic drugs, old molecules as new tools against the COVID-19?

40

Molecular basis for the repurposing of histamine H2-receptor antagonist to treat COVID-19.

Structure métallique
Abstract Lights

41

Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis.

42

Brief Summary:

This study is a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of cetirizine and famotidine in reducing the duration of symptoms in patients with COVID-19. Secondary aims are to determine if cetirizine and famotidine decrease severity and duration of symptoms, incidence of hospitalizations, ICU admissions, and death.

Structure métallique
Abstract Lights

43

Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells.

44

A Review of Its Mechanism of Action and Its Role in COVID-19.

​

Antidepressants also decrease histamine release from MCs (Ferjan and Erjavec, 1996).

​

Structure métallique
Abstract Lights

45

Long-Covid following mild SARS Cov-2 infection: characteristic T cell alterations and response to antihistamines.

46

Highlights

 

•Early cardiac pathology likely caused by vasoconstriction ischemia then anoxia

•Ischemia and anoxia possibly caused by vasoconstriction of cardiac pericyte cells

•Vasoconstrictions likely caused by histamine or SARS-CoV-2 pericyte infection

Structure métallique
Abstract Lights

47

summary of therapeutic evidence for Covid-19 around the world.

48

The beneficial use of two types of antihistamine drug – known as H1 and H2 histamine antagonists

 

​

Structure métallique
Abstract Lights

49

Strategy for managing COVID-19 Dr Chris Newton

50

Refer to proposed evaluation and treatment options for this hypothesis

Structure métallique
Abstract Lights

51

COVID-19 HISTAMINE THEORY. WHY SHOULD WE APPROVE ANTI-HISTAMINES FOR COVID-19 AS A PROPHYLAXIS AND A TREATMENT?

52

Update on functional inhibitors of acid sphingomyelinase in SARS-CoV-2 infection

Structure métallique
Abstract Lights

53

Mast cells and Histamine storm an overlooked aspect in Covid-19 and in ventilated patients - potential role of antihistamine.

54

Loratadine is successfully used to fix COVID-19 induced respiratory distress and chest pain.

Structure métallique
Abstract Lights

55

terrible dizzy spells, crippling fatigue, and heart problems and antihistamines

56

Resolution of symptoms after administration of over-the-counter histamine antagonists.

Structure métallique
Abstract Lights

57

Covid long : antihistaminiques pour les patients souffrant de séquelles du Covid.

58

Phase 2 Clinical Trial patients with Covid-19

Structure métallique
Abstract Lights

59

Exploring the association of previous hospitalisation use of medication on the mortality of Covid-19 disease January 2022.

60

Covid‐19 Histamine theory

Structure métallique
Abstract Lights

61

By targeting cellular protein activity, they are uniquely positioned to treat the symptoms of COVID-19.

bottom of page